


L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 51322-75-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN Tizanidine
MF C9 H8 Cl N5 S
CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS,
BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU,
DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS,
IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS,
RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

258 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
258 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 181695-72-7 REGISTRY
ED Entered STN: 10 Oct 1996
CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide

CN Bextra

CN SC 65872

CN Valdecoxib


CN Valecoxib

MF C16 H14 N2 O3 S

CI COM

SR CA

LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CSCHEM, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

599 REFERENCES IN FILE CA (1907 TO DATE)

26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

604 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "TIZANIDINE"/CN 25

E1	1	TIZ 80/2/CN
E2	1	TIZABRIN/CN
E3	1 -->	TIZANIDINE/CN
E4	1	TIZANIDINE HYDROCHLORIDE/CN
E5	1	TIZANIDINE-IBUPROFEN MIXT./CN
E6	1	TIZANOX/CN
E7	1	TIZATE B/CN
E8	1	TIZIAN RED/CN
E9	1	TIZIDE/CN
E10	1	TIZINE/CN
E11	1	TIZOLE/CN
E12	1	TIZOLEMIDE/CN
E13	1	TIZON/CN
E14	1	TIZOPROLIC ACID/CN
E15	1	TIZOXANIDE/CN
E16	1	TIZOXANIDE GLUCURONIDE/CN
E17	1	TIZRYAL-1/CN
E18	1	TIZRYAL-2/CN
E19	2	TJ/CN
E20	1	TJ (ACRYLIC POLYMER)/CN
E21	1	TJ (COMPLEXING AGENT)/CN
E22	1	TJ 04CN/CN
E23	1	TJ 05/CN
E24	1	TJ 066/CN
E25	1	TJ 1/CN

=> S E3

L1 1 TIZANIDINE/CN

=> DIS L1 1 IDE

THE ESTIMATED COST FOR THIS REQUEST IS 1.90 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 51322-75-9 REGISTRY

ED Entered STN: 16 Nov 1984

CN 2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-(9CI) (CA INDEX NAME)

OTHER NAMES:


CN Tizanidine

MF C9 H8 Cl N5 S

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSChem, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCoSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

258 REFERENCES IN FILE CA (1907 TO DATE)

7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

258 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> E "TIZANIDINE"/CN 25

E1	1	TIZ 80/2/CN
E2	1	TIZABRIN/CN
E3	1 -->	TIZANIDINE/CN
E4	1	TIZANIDINE HYDROCHLORIDE/CN
E5	1	TIZANIDINE-IBUPROFEN MIXT./CN
E6	1	TIZANOX/CN
E7	1	TIZATE B/CN
E8	1	TIZIAN RED/CN
E9	1	TIZIDE/CN
E10	1	TIZINE/CN
E11	1	TIZOLE/CN
E12	1	TIZOLEMIDE/CN
E13	1	TIZON/CN
E14	1	TIZOPROLIC ACID/CN
E15	1	TIZOXANIDE/CN
E16	1	TIZOXANIDE GLUCURONIDE/CN
E17	1	TIZRYAL-1/CN
E18	1	TIZRYAL-2/CN
E19	2	TJ/CN
E20	1	TJ (ACRYLIC POLYMER)/CN
E21	1	TJ (COMPLEXING AGENT)/CN
E22	1	TJ 04CN/CN
E23	1	TJ 05/CN
E24	1	TJ 066/CN
E25	1	TJ 1/CN

=> E "VALDECOXIB"/CN 25

E1	1	VALCYTE/CN
E2	1	VALDAMAR/CN
E3	1 -->	VALDECOXIB/CN
E4	1	VALDECOXIB POTASSIUM/CN
E5	1	VALDECOXIB SODIUM/CN
E6	1	VALDET 4016/CN
E7	1	VALDET 79N/CN
E8	1	VALDETAMIDE/CN
E9	1	VALDIATE/CN
E10	1	VALDIBERINE/CN
E11	1	VALDIBERINE DIACETATE/CN
E12	1	VALDICE/CN
E13	1	VALDIPROMIDE/CN
E14	1	VALDISOVAL/CN
E15	1	VALDISPERT/CN
E16	1	VALDIVIANINE/CN

E17	1	VALDIVIANINE ACETATE/CN
E18	1	VALDIVIN/CN
E19	1	VALDIVIN, DIHYDRATE/CN
E20	1	VALDIVIOLIDE/CN
E21	1	VALDIVIONE/CN
E22	1	VALDIVONE A/CN
E23	1	VALDIVONE B/CN
E24	1	VALEANS/CN
E25	1	VALECHLORIN/CN

=> S E3

L2 1 VALDECOXIB/CN

=> DIS L2 1 IDE

THE ESTIMATED COST FOR THIS REQUEST IS 1.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 181695-72-7 REGISTRY

ED Entered STN: 10 Oct 1996

CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME).

OTHER NAMES:

CN 4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide

CN Bextra

CN SC 65872

CN Valdecoxib


CN Valecoxib

MF C16 H14 N2 O3 S

CI COM

SR CA

LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CSCHEM, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

599 REFERENCES IN FILE CA (1907 TO DATE)

26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

604 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	14.64	14.85

FILE 'CAPLUS' ENTERED AT 09:45:07 ON 11 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Oct 2006 VOL 145 ISS 16
FILE LAST UPDATED: 9 Oct 2006 (20061009/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 181695-72-7

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L4 604 L3

=> s 51322-75-9

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L6 258 L5

=> s l4 and l6

L7 5 L4 AND L6

=> d ti au abs so py 1-5

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Pharmaceutical compositions comprising an agent with serotonin receptor modulating activity for sleep disorders

IN Rariy, Roman V.; Heffernan, Michael

AB Pharmaceutical compns. are provided for the pharmacol. treatment of breathing disorders and, more specifically, to compns. containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma concns. across the period of sleep. For example, ondansetron immediate release tablets were prepared containing ondansetron HCl dihydrate 9.98 mg, lactose 29.14 mg, Prosolv 50 29.14 mg, Ac-Di-Sol 3.75 mg, SDS 1.5 mg, Aerosil 0.75 mg, and Mg stearate 0.75 mg. Ondansetron immediate release tablets were then coated with Eudragit L100/S100 blend to obtain delayed release tablets.

SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2

PY 2006

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Simultaneous estimation of valdecoxib and tizanidine by Vierodt's and Q-analysis UV spectrophotometric method

AU Nagulwar, Vaishali; Tajne, M. R.; Upadhye, Kanchan; Bakhle, Suparna; Deshpande, Shilpa; Wadetwar, Rita

AB The simple, accurate and precise Vierodt's and Q-anal. UV Spectrophotometric method was developed for the simultaneous determination of valdecoxib and tizanidine in combined tablet dosage form. Shimadzu UV-1601 instrument was used and the λ_{max} of valdecoxib and tizanidine was found to be 237 nm and 319 nm, resp. In Q-anal., the isoabsorptive point for both the drugs was found at 289.5 nm. The linearity range lies between 5-30 $\mu\text{g/mL}$ for valdecoxib and 0.5-3 $\mu\text{g/mL}$ for tizanidine at their resp. wavelengths.

SO Indian Journal of Pharmaceutical Sciences (2005), 67(5), 624-627
CODEN: IJSIDW; ISSN: 0250-474X

PY 2005

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Pharmaceutical formulation containing muscle relaxant and cox-ii inhibitor

IN Sen, Nilendu; Chandurkar, Kavita; Krishnan, Anandi

AB Disclosed is an extended release pharmaceutical formulation comprising a muscle relaxant drug, such as tizanidine, in combination with a cyclooxygenase-2 inhibitor, such as valdecoxib. The formulations are useful in the treatment and management of painful inflammatory conditions associated with, for example, skeletal muscle spasms. For example, capsules containing tizanidine 6 mg extended release formulation and valdecoxib 20 mg immediate release formulation have good drug bioavailability.

SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO

PY 2005

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

TI Stereoisomers of p-hydroxy-milnacipran, and therapeutic use

IN Rariy, Roman V.; Heffernan, Michael; Buchwald, Stephen L.; Swager, Timothy M.

AB The invention relates generally to the enantiomers of p-hydroxymilnacipran or congeners thereof. Biol. assays revealed that racemic p-hydroxymilnacipran is approx. equipotent in inhibiting serotonin and norepinephrine uptake (IC_{50} = 28.6 nM for norepinephrine, IC_{50} = 21.7 nM for serotonin). Interestingly, (+)-p-hydroxymilnacipran is a more potent inhibitor of norepinephrine uptake than serotonin uptake (IC_{50} = 10.3 nM for norepinephrine, IC_{50} = 22 nM for serotonin). In contrast, (-)-p-hydroxymilnacipran is a more potent inhibitor of serotonin uptake compared to norepinephrine uptake (IC_{50} = 88.5 nM for norepinephrine, IC_{50} = 40.3 nM for serotonin). The invention also relates to salts and prodrug forms of the above compds. In certain embodiments, the compds. of the invention and a pharmaceutically acceptable excipient are combined to prepare a formulation for administration to a patient. Finally, the

invention relates to methods of treating mammals suffering from various afflictions, e.g., depression, chronic pain, or fibromyalgia, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of the invention. Compound preparation is included.

SO PCT Int. Appl., 163 pp.
CODEN: PIXXD2

PY 2004
2004
2004
2004
2004
2006
2005
2006

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Novel pharmaceuticals comprising drug conjugates with polypeptide carriers
IN Picariello, Thomas
AB A pharmaceutical composition comprising a polypeptide and an active agent attached to said polypeptide is disclosed.

SO PCT Int. Appl., 2059 pp.
CODEN: PIXXD2

PY 2003
2003
2003
2003
2006
2004
2006

=> s controlled(w)release or capsule or tablet or extended(w)release

534697 CONTROLLED
1 CONTROLLED
534697 CONTROLLED
(CONTROLLED OR CONTROLLED)

475342 RELEASE
23823 RELEASES
489594 RELEASE
(RELEASE OR RELEASES)

20580 CONTROLLED (W) RELEASE

38410 CAPSULE
41037 CAPSULES
63622 CAPSULE

(CAPSULE OR CAPSULES)

45085 TABLET

69928 TABLETS

81195 TABLET

(TABLET OR TABLETS)

245029 EXTENDED

3 EXTENDED

245032 EXTENDED

(EXTENDED OR EXTENDED)

475342 RELEASE

23823 RELEASES

489594 RELEASE

(RELEASE OR RELEASES)

1535 EXTENDED (W) RELEASE

L8 145812 CONTROLLED (W) RELEASE OR CAPSULE OR TABLET OR EXTENDED (W) RELEASE

=> s 14 and 16 and 18

L9 4 L4 AND L6 AND L8

=> dup rem

ENTER L# LIST OR (END):19

PROCESSING COMPLETED FOR L9

L10 4 DUP REM L9 (0 DUPLICATES REMOVED)

ANSWERS '1-4' FROM FILE CAPLUS

=> d ti au abs so py 1-4

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Pharmaceutical compositions comprising an agent with serotonin receptor modulating activity for sleep disorders

IN Rariy, Roman V.; Heffernan, Michael

AB Pharmaceutical compns. are provided for the pharmacol. treatment of breathing disorders and, more specifically, to compns. containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma concns. across the period of sleep. For example, ondansetron immediate release tablets were prepared containing ondansetron HCl dihydrate 9.98 mg, lactose 29.14 mg, Prosolv 50 29.14 mg, Ac-Di-Sol 3.75 mg, SDS 1.5 mg, Aerosil 0.75 mg, and Mg stearate 0.75 mg. Ondansetron immediate release tablets were then coated with Eudragit L100/S100 blend to obtain delayed release tablets.

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2

PY 2006

L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Pharmaceutical formulation containing muscle relaxant and cox-ii inhibitor

IN Sen, Nilendu; Chandurkar, Kavita; Krishnan, Anandi

AB Disclosed is an extended release pharmaceutical formulation comprising a muscle relaxant drug, such as tizanidine, in combination with a cyclooxygenase-2 inhibitor, such as valdecoxib. The formulations are useful in the treatment and management of painful inflammatory conditions associated with, for example, skeletal muscle spasms. For example, capsules containing tizanidine 6 mg extended release formulation and valdecoxib 20 mg immediate release formulation have good drug bioavailability.

SO U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

PY 2005

2005

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Simultaneous estimation of valdecoxib and tizanidine by Vierodt's and Q-analysis UV spectrophotometric method

AU Nagulwar, Vaishali; Tajne, M. R.; Upadhye, Kanchan; Bakhle, Suparna; Deshpande, Shilpa; Wadetwar, Rita

AB The simple, accurate and precise Vierodt's and Q-anal. UV Spectrophotometric method was developed for the simultaneous determination of valdecoxib and tizanidine in combined tablet dosage form. Shimadzu UV-1601 instrument was used and the λ_{max} of valdecoxib and tizanidine was found to be 237 nm and 319 nm, resp. In Q-anal., the isoabsorptive point for both the drugs was found at 289.5 nm. The linearity range lies between 5-30 $\mu\text{g/mL}$ for valdecoxib and 0.5-3 $\mu\text{g/mL}$ for tizanidine at their resp. wavelengths.

SO Indian Journal of Pharmaceutical Sciences (2005), 67(5), 624-627

CODEN: IJSIDW; ISSN: 0250-474X

PY 2005

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Novel pharmaceuticals comprising drug conjugates with polypeptide carriers

IN Picariello, Thomas

AB A pharmaceutical composition comprising a polypeptide and an active agent attached to said polypeptide is disclosed.

SO PCT Int. Appl., 2059 pp.
CODEN: PIXXD2
PY 2003
2003
2003
2003
2006
2004
2006

=>